X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (NASDAQ:XFOR)
· seekingalpha.com
X4 Pharmaceuticals could receive up to €221M in additional regulatory and commercial milestones and royalties. See why XFOR stock is downgraded to a hold.
X4 Pharmaceuticals ( XFOR ) has delivered on the majority of items we expected in our March 3, 2026 coverage. The European Commission approved XOLREMDI for WHIM...